Condition
Soft Tissue Sarcoma|Mesothelioma
Estimated Enrollment: 28
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: AAAC3255
Study First Received: February 26, 2008
Last Updated: November 7, 2012
Estimated Primary Completion Date: October 2012
Primary Outcome Measures:
The primary endpoint is dose limiting toxicity.|Clinical response, time to progression and overall survival.
Sponsors and Collaborators:
Columbia University|Schering-Plough|Celgene Corporation
Website Link: https://ClinicalTrials.gov/show/NCT00629343
